Regulatory shift puts GH Research (NasdaqGM:GHRS) in focus
The US Food and Drug Administration’s finalized guidance on psychedelic drug development, along with a planned public hearing on supervised psychedelic use, has put GH Research (NasdaqGM:GHRS) firmly back on investors’ radar.
This clearer regulatory direction may influence how investors think about regulatory risk, sector accessibility, and valuation frameworks for clinical-stage psychedelic developers, particularly those targeting treatment-resistant depression and related mood disorders.
See our latest analysis for GH Research.
Against this regulatory backdrop, GH Research’s recent price action has been strong, with the share price at $26.77 after a 1 day share price return of 5.60%, a 30 day share price return of 26.75% and a year to date share price return of 102.19%. The 1 year total shareholder return of 67.42% and 3 year total shareholder return of 104.35% point to momentum that investors are reassessing in light of changing perceptions of regulatory risk.
If the regulatory shift around psychedelics has your attention, it may be a good time to broaden your watchlist using our screener for 40 healthcare AI stocks
After a move that has already lifted GH Research more than 100% year to date, the key question now is straightforward: is most of the upside already in the rearview mirror, or does the valuation still leave meaningful room ahead?
Preferred price-to-book multiple of 7x for GH Research: Is it justified?
At a last close of $26.77, GH Research is currently trading on a P/B of 7x, which screens as expensive compared with both peers and the wider US Pharmaceuticals industry.
The price to book ratio compares the company’s market value to its net assets, which is a common way to look at pre revenue, loss making biopharmaceutical stocks where earnings based measures are less useful. In GH Research’s case, investors are paying a higher multiple of book value despite the company reporting a loss of $56.413m and making less than $1m in revenue.
Relative to peers on 6.4x P/B and an industry average of 2.3x, the 7x multiple stands out as a premium, suggesting the market is assigning a higher value to GH Research’s pipeline and clinical progress than to the typical US Pharmaceuticals company.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 7x (OVERVALUED).
However, GH Research still carries key risks, including clinical trial setbacks for GH001 or GH002, as well as any shift in FDA guidance that cools sentiment around psychedelics.
Find out about the key risks to this GH Research narrative.
Next Steps
With GH Research back in focus and regulatory sentiment shifting, it makes sense to review the underlying data yourself and move quickly to frame your own view using the 2 important warning signs.
Looking for more investment ideas beyond GH Research?
If GH Research has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to line up your next set of opportunities.
- Target potential value opportunities by scanning through 44 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
- Prioritize resilience and sleep a little easier at night by checking out 79 resilient stocks with low risk scores with historically lower overall risk scores.
- Spot lesser known opportunities before the crowd by reviewing the screener containing 20 high quality undiscovered gems with solid underlying fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com